Pharmacokinetic and pharmacodynamic research in the intensive care unit: An unmet need

Critical Care Medicine

Volumn 34, Issue 6, 2006, Pages 1831-1833

  Haas, Curtis E ^a,b   Forrest, Alan ^a,c,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Critical illness; Erythropoeitin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

AREA UNDER THE CURVE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SAFETY; EDITORIAL; ERYTHROPOIESIS; HUMAN; INFLAMMATION; INTENSIVE CARE; INTENSIVE CARE UNIT; MEDICAL RESEARCH; MONITORING; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SEPSIS;

ANEMIA; CRITICAL ILLNESS; EPOETIN ALFA; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE UNITS; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

EID: 33744530847     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000219372.32810.20     Document Type: Editorial

References (18)

1. Beizberg H, Zhu J, Cornwell EE III, et al: Imipenem levels are not predictable in the critically ill patient. J Trauma 2004; 56:111-117
2. Carcillo JA, Doughty L, Kofos D, et al: Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29:980-984
3. McKindley DS, Hanes S, Boucher BA: Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18:759-778
4. Power BM, Forbes AM, van Heerden PV, et al: Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34:25-56
5. Wagner BK, O'Hara DA: Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet 1997; 33:426-453
6. Johnston AJ, Steiner LA, O'Connell M, et al: Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients. Intensive Care Med 2004; 30:45-50
7. Mohr JF, Wanger A, Rex JH: Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial Gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004; 48:125-130
8. Yamamura S: Clinical application of artificial neural network (ANN) modeling to predict pharmacokinetic parameters of severely ill patients. Adv Drug Deliv Rev 2003; 55:1233-1251
9. Vincent JL, Spapen HDMH, Creteur J, et al: Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006; 34:1661-1667
10. Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
11. MacLaren R, Sullivan PW: Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 2005; 8:105-116
12. Shermock KM, Horn E, Lipsett PA, et al: Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005; 33:497-503
13. Krzyzanski W, Jusko WJ, Wacholtz MC, et al: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Ear J Pharm Sci 2005; 26:295-306
14. Ramakrishnan R, Cheung WK, Wacholtz MC, et al: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004; 44:991-1002
15. Veng-Pedersen P, Widness JA, Pereira LM, et al: A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999; 20:217-223
16. Jin F, Krzyzanski W: Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci 2004; 6:E9
17. Coleman T, Brines M: Science review: Recombinant human erythropoietin in critical illness. A role beyond anemia? Crit Care 2004; 8:337-341
18. Darveau M, Denault AY, Blais N, et al: Bench-to-bedside review: Iron metabolism in critically ill patients. Crit Care 2004; 8:356-362